Mild Cognitive Impairment
Conditions
Interventions
2mA tDCS group:The tDCS anode was placed over the right dorsolateral prefrontal cortex (DLPFC) of the subject, and the cathode was placed above the left orbit. The stimulation intensity was set at 2 m
1mA tDCS group:The tDCS anode was placed over the right dorsolateral prefrontal cortex (DLPFC) of the subject, and the cathode was placed above the left orbit. The stimulation intensity was set at 1 m
shame stimulation group:The tDCS anode was placed over the right dorsolateral prefrontal cortex (DLPFC) of the subject, and the cathode was placed above the left orbit. A 30-second ramp-up and ramp-do
Sponsors
Rehabilitation Industry Institute, School of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine; The Third People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for MCI; 2. 18 < MoCA < 26; if the years of education are = 12 years, add 1 point to the obtained score; 3. Score < 22 on the Activities of Daily Living (ADL) scale; 4. Score between Grade 2 and Grade 3 on the Global Deterioration Scale (GDS); 5. Age between 50 and 75 years; 6. No contraindications to tDCS treatment, such as wearing a pacemaker, having skull defects or fissures, or being unable to tolerate adverse reactions; 7. The subject has given informed consent and voluntarily participates in the study.
Exclusion criteria
Exclusion criteria: 1. Patients with cognitive impairment caused by depression, with a score = 9 on the Geriatric Depression Scale (GDS); 2. Patients with cognitive impairment resulting from other causes, such as medication use (e.g., antipsychotics, benzodiazepines), poisoning, etc.; 3. Patients with vascular mild cognitive impairment (VaMCI); 4. Patients with epilepsy; 5. Individuals unable to complete outcome assessments, such as those with severe aphasia, audiovisual impairment, illiteracy, etc.; 6. Individuals currently participating in other clinical trials that may affect the evaluation of outcomes in this study; 7. Individuals who have taken medications that may affect or improve cognitive function within the past six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chinese revised version of the Wechsler Adult Memory Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale;Auditory word learning test;Alzheimer's Disease Assessment Scale - Cognitive Subscale ;N-Back working memory test;Delay matching sample test;EEG neural rhythms;Cerebral blood oxygen concentration;Stroop Color-Word Test;Trail Making Test Part B;Pittsburgh Sleep Quality Index; | — |
Countries
China
Contacts
Public ContactXu Ying, Chen Xueling
Rehabilitation Industry Institute, School of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine; The Third People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine
Outcome results
None listed